Postoperative pain after total knee replacement. Which non-steroidal antiinflammatory drugs should be used? Postoperative pain after total knee arthroplasty is a major concern for both patients undergoing the procedure and doctors, as it is difficult to control and can be quite extreme. Currently, a mixture of NSAIDs and opioids is commonly used in order to alleviate the pain, however it is still not known which NSAIDs are the most effective in terms of pain management and side-effect control. Accordingly, there are no respective guidelines. The aim and objective of this structured review was to search, identify, review and critically appraise the existing articles, relevant to the topic. The study was designed as a systematic review, focusing on the selection/usage of NSAIDs in postoperative pain management in patients after total knee replacement.
The online databases (PubMed  1 and Scopus   2 ) were searched and articles that met the inclusion criteria e i.e. Randomised controlled trials; articles published after 01/12/ 1999; specific procedure e total knee arthroplasty; specific type of pain e postoperative pain; NSAIDs usage as the main type of adjunctive analgesics were identified. The main exclusion criteria were: Additional different analgesic techniques; nonhuman species; full text not available online.
We critically appraised the articles using PRISMA statement 3 and CASP checklists 4 , and summarised and compared the obtained results. Overall, five articles meeting the set criteria were identified to be relevant to this review. In particular, we looked at the levels of pain and incidence of opioid-related side-effects as outcome measures for each paper reviewed.
The review established that five different NSAIDs in combination with opioids had been used (Lornoxicam, Parecoxib sodium, Etoricoxib, Tenoxicam, and Celecoxib). All these drugs contributed to varying degrees to postoperative analgesia, however only Lornoxicam showed a significant opioid-sparing effect, thereby decreasing the incidence of opioid related side-effects. 5 This systematic review shows that so far there is very limited Level 1b evidence 6 to support a rational choice of NSAIDs as adjuncts to postoperative analgesia after total knee arthroplasty. Consequently, further clinical research is necessary. A particular focus on the effects of Lornoxicam in this context may have merit.
Ratifying the dosage and duration of levobupivacaine infusion by the caudal-epidural route in infants aged three to six months The pharmacokinetics of levo-bupivocaine are age-dependent. 1 Current paediatric protocols for caudal-epidural infusions of levo-bupivacaine are derived from bupivacaine-based pharmacokinetic modelling aiming for plasma levels below 2-2.5 mg/ ml 2 . Levo-bupivacaine levels have been evaluated following single caudal-epidural boluses 3 . However, no studies have investigated this in infants less than 6 months with a single bolus followed by an infusion. This phase-II/III clinical trial aims to validate levo-bupivacaine pharmacokinetic modelling in infants aged 3-6months and ensure that toxic levels are not being reached by present protocols of levo-bupivacaine (i.e. Abstracts -e11 bolus followed by an infusion). This would inform clinical practice and dosing for major surgical procedures.
Ethics approval: Northwest Research Ethics Committee(15/ NW/0240) and MHRA (EudraCT 2015-000393-0034). After informed parental consent, 8 infants, aged 3e6 months undergoing bladder exstrophy repair were included. They had a tunnelled caudal-epidural catheter (20G 'Arrow' reinforcedflexi-tip) inserted under general anaesthesia with invasivearterial and central-venous pressure monitoring. Surgery took 6e10 hours: closure of bladder and abdominal wall, anterior pelvic osteotomies and external pelvic fixation. Infants received a bolus of 2.0 mg/kg, 0.25% levo-bupivacaine via caudal-epidural catheter, followed by an infusion of 0.2 mg/kg/ hr 0.125% levo-bupivacaine with clonidine (1.5 mg/ml), initiated after 60 minutes and continued for 48hours. A literature-based levo-bupivacaine and a1-acid glycoprotein(AAG) model was developed to predict the impact of surgical alteration of AAG levels (an acute phase protein) on total levo-bupivacaine concentrations. Blood samples were obtained at predetermined intervals up to 72 hours and total plasma levels of levo-bupivacaine and AAG were analysed. Population pharmacokinetic modelling was carried out to analyse the generated clinical data (total levo-bupivacaine and AAG) using NONMEM7.3 (ICON plc, Dublin, Ireland).
Complete results were obtained from 6-out-of-8 patients. Maximum plasma level of total levo-bupivacaine at 1 hour was 0.7 mg/ml. (range¼0.20e0.7). Maximum total levo-bupivacaine observed at 48 hours was 1.85 mg/ml (range¼0.07e1.85). Serum AAG levels also continued to rise up to 72 hours. But, the simulated unbound levo-bupivacaine levels, based on the current model, suggests that unbound levo-bupivacaine quickly reaches steady state concentrations following the loading dose and is maintained at a constant level of around 0.03mg/ml throughout the infusion period (Fig. 3) .
This trial validates the pharmacokinetic model and we conclude that in-spite of the increase in total levo-bupivacaine over 48hours, due to the increase in AAG, the unbound levobupivacaine level is maintained at a steady state, well below the predicted toxic levels. Elective Hip And Knee Arthroplasty (HAKA) audit looking at anaesthetic technique, postop pain scores, nausea, vomiting, first mobilisation times, patient satisfaction and days until discharge prior to the implementation of an enhanced recovery pathway at Pilgrim Hospital Demand is increasing for elective hip and knee arthroplasties. At Pilgrim Hospital, no consensus existed for the preferred anaesthetic technique. The balance is between anaesthetic technique, good post-op analgesia and early mobilisation. The shared goal is ultimately a good patient journey and early discharge. Enhanced recovery pathways for hip and knee arthroplasties are being used in other hospitals nationwide and their effectiveness studied 1, 2, 3 . The aim of this audit is to provide evidence of current management and to roll-out an enhanced recovery pathway. This is a prospective data collection of elective Hip and Knee arthroplasties. Over 11/5/16 to 16/6/16. We included patients receiving Spinals (with or without diamorphine) and general anaesthesia (with or without regional blocks which included femoral, sciatic and/or iliac). We collected: visual analogue pain scores (0e10) in recovery and every six hours for three days; incidence of nausea and vomiting; time until first mobilisation; patient satisfaction and days until discharge. We used a data collection form and 'WebV' electronic system. Total 52 patients. 28 Hips (7 Revisions). 24 Knees (1 Revision). Average age 70 yrs and ASA 2. For full results see Table 2 . Morphine patient controlled analgesia (PCA) was used for 25 patients with similar usage on day 1 of 19 mg average and satisfaction rating of 'good/very good'. Without PCA it was 'good' despite comparatively less oral morphine. Mobilisation and discharge was delayed for 1) Knees with PCA vs oral morphine (not apply to hips) 2) Hip and knees with blocks. With blocks post-op analgesic requirements were higher with higher pain scores and worse patient satisfaction. Pain, mobilisation and discharge with diamorphine in spinals is comparable to those spinals without diamorphine but incidence of nausea is more with diamorphine. Primary vs revisions: Hip mobilisation and discharge is comparable but for knees is longer for revisions.
There are some limitations such as sample size. Pain scores are subjective and occasionally retrospective which limits their comparison. PCA dose documentation varied. There were three post-op complications reducing weight of discharge data. Experience of operator for regional block not collected. Incidence of Urinary retention not collected.
